Patents by Inventor Karl D. Normington

Karl D. Normington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11957703
    Abstract: The invention provides methods of modulating and regulating NHD protein-protein interactions through nicotinamide mononucleotide, analogs and derivatives thereof, such as NAD+. Such modulation may be useful in methods of treating and preventing cancer, aging, cell death, radiation damage, radiation exposure, among others, may improve DNA repair, cell proliferation, cell survival, among others, and may increase the life span of a cell or protect it against certain stresses, among others.
    Type: Grant
    Filed: May 5, 2022
    Date of Patent: April 16, 2024
    Assignees: President and Fellows of Harvard College, Metro International Biotech, LLC
    Inventors: David A. Sinclair, Jun Li, Karl D. Normington
  • Patent number: 11878027
    Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    Type: Grant
    Filed: July 26, 2022
    Date of Patent: January 23, 2024
    Assignee: Metro International Biotech, LLC
    Inventors: Karl D. Normington, David A. Sinclair, David J. Livingston, James M. McKearin, Bruce Szczepankiewicz, Jonathan N. Kremsky
  • Publication number: 20230293569
    Abstract: The invention provides methods of modulating and regulating NHD protein-protein interactions through nicotinamide mononucleotide, analogs and derivatives thereof, such as NAD+. Such modulation may be useful in methods of treating and preventing cancer, aging, cell death, radiation damage, radiation exposure, among others, may improve DNA repair, cell proliferation, cell survival, among others, and may increase the life span of a cell or protect it against certain stresses, among others.
    Type: Application
    Filed: May 5, 2022
    Publication date: September 21, 2023
    Inventors: David A. SINCLAIR, Jun Li, Karl D. Normington
  • Publication number: 20230158053
    Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    Type: Application
    Filed: July 26, 2022
    Publication date: May 25, 2023
    Inventors: Karl D. Normington, David A. Sinclair, David J. Livingston, James M. McKearin, Bruce Szczepankiewicz, Jonathan N. Kremsky
  • Publication number: 20220362351
    Abstract: The invention relates generally to recombinant sialidases, methods and compositions for extending the serum half-life of the recombinant sialidases, and use of the same in the treatment of a sialic acid-related disorder.
    Type: Application
    Filed: July 3, 2020
    Publication date: November 17, 2022
    Inventors: Li Peng, Lizhi Cao, Sandip A. Shelke, Andrew S. Turner, Lihui Xu, Wayne C. Gatlin, James W. Broderick, Karl D. Normington, Sujata B. Nerle, Zakir B. Siddiquee, Abhishek Das
  • Patent number: 11464796
    Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: October 11, 2022
    Assignee: Metro International Biotech, LLC
    Inventors: Karl D. Normington, David A. Sinclair, David J. Livingston, James M. McKearin, Bruce Szczepankiewicz, Jonathan N. Kremsky
  • Publication number: 20210253695
    Abstract: The present application provides compositions and methods for treating a patient with cancer, and in particular epithelial tumors and carcinomas, with antibodies directed to CD33-like Siglecs.
    Type: Application
    Filed: October 26, 2020
    Publication date: August 19, 2021
    Inventors: James W. Broderick, Karl D. Normington
  • Publication number: 20200352966
    Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    Type: Application
    Filed: December 13, 2019
    Publication date: November 12, 2020
    Inventors: Karl D. Normington, David A. Sinclair, David J. Livingston, James M. McKearin, Bruce Szczepankiewicz, Jonathan N. Kremsky
  • Patent number: 10548913
    Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: February 4, 2020
    Assignee: Metro International Biotech, LLC
    Inventors: Karl D. Normington, David A. Sinclair, David J. Livingston, James M. McKearin, Bruce Szczepankiewicz, Jonathan N. Kremsky
  • Publication number: 20190350960
    Abstract: The invention provides methods of modulating and regulating NHD protein-protein interactions through nicotinamide mononucleotide, analogs and derivatives thereof, such as NAD+.
    Type: Application
    Filed: January 3, 2018
    Publication date: November 21, 2019
    Inventors: David A. SINCLAIR, Jun Li, Karl D. Normington
  • Publication number: 20190023786
    Abstract: The present application provides compositions and methods for treating a patient with cancer, and in particular epithelial tumors and carcinomas, with antibodies directed to CD33-like Siglecs.
    Type: Application
    Filed: January 12, 2017
    Publication date: January 24, 2019
    Inventors: James Broderick, Karl D. Normington
  • Publication number: 20180147227
    Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    Type: Application
    Filed: January 23, 2018
    Publication date: May 31, 2018
    Inventors: Karl D. Normington, David A. Sinclair, David J. Livingston, James M. Mckearin, Bruce Szczpankiewicz, Jonathan N. Kremsky
  • Patent number: 9919003
    Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: March 20, 2018
    Assignee: Metro International Biotech, LLC
    Inventors: Karl D. Normington, David A. Sinclair, David J. Livingston, James M. McKearin, Bruce Szczpankiewicz, Jonathan N. Kremsky
  • Patent number: 9855289
    Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: January 2, 2018
    Assignee: Metro International Biotech, LLC
    Inventors: Karl D. Normington, David A. Sinclair, David J. Livingston, James M. McKearin, Bruce Szczpankiewicz, Jonathan N. Kremsky
  • Publication number: 20170290850
    Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    Type: Application
    Filed: August 5, 2016
    Publication date: October 12, 2017
    Inventors: Karl D. Normington, David A. Sinclair, David J. Livingston, James M. McKearin, Bruce Szczpankiewicz, Jonathan N. Kremsky
  • Publication number: 20170189434
    Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    Type: Application
    Filed: March 20, 2017
    Publication date: July 6, 2017
    Inventors: Karl D. Normington, David A. Sinclair, David J. Livingston, James M. McKearin, Bruce Szczpankiewicz, Jonathan N. Kremsky
  • Publication number: 20150175645
    Abstract: Provided herein are sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    Type: Application
    Filed: July 24, 2014
    Publication date: June 25, 2015
    Inventors: Michael MILBURN, Jill MILNE, Karl D. NORMINGTON, Joseph J. NUNES, Thomas SALZMANN, David SINCLAIR, Christoph H. WESTPHAL
  • Patent number: 7998974
    Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, chemotherapeutic induced neuropathy, neuropathy associated with an ischemic event, polyglutamine diseases, ocular diseases and/or disorders, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: August 16, 2011
    Assignee: Sirtris Pharmaceuticals, Inc.
    Inventors: Michael Milburn, Jill Milne, Jean Bemis, Joseph J. Nunes, Roger Xie, Karl D. Normington, Chi B. Vu
  • Publication number: 20090163476
    Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    Type: Application
    Filed: March 3, 2006
    Publication date: June 25, 2009
    Applicant: Sirtris Pharmaceuticals, Inc.
    Inventors: Michael Milburn, Jill Milne, Jean Bemis, Joseph J. Nunes, Roger Xie, Karl D. Normington, Chi B. Vu
  • Publication number: 20090069301
    Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, chemotherapeutic induced neuropathy, neuropathy associated with an ischemic event, polyglutamine diseases, ocular diseases and/or disorders, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    Type: Application
    Filed: March 3, 2006
    Publication date: March 12, 2009
    Applicant: Sirtris Pharmaceuticals, Inc.
    Inventors: Michael Milburn, Jill Milne, Jean Bemis, Joseph J. Nunes, Roger Xie, Karl D. Normington